REGENXBIO Investors Face April 14 Deadline to Seek Lead Role in RGX-111 Securities Suit

Overview

• Plaintiff firms, including Rosen Law Firm and Faruqi & Faruqi, are urging REGENXBIO investors to move by April 14, 2026 to be considered for lead plaintiff.
• The lawsuit says the company touted positive biomarker and safety signals for RGX-111 while hiding adverse facts about the therapy’s efficacy and risks.
• RGX-111 is a one-time gene therapy candidate for severe Mucopolysaccharidosis Type I, also known as Hurler syndrome.
• REGENXBIO reported an FDA clinical hold on RGX-111 on January 28, 2026, and the stock fell 17.9% that day to close at $11.01.
• No class has been certified, so the court will choose a lead plaintiff next, which could shape discovery and the direction of the case.